Quotient are delighted to host a gathering of inhaled medicine experts at the next European Pharmaceutical Aerosol Group (EPAG) meeting. The meeting will be held at Quotient’s headquarters in Nottingham on the 5th and 6th July.
EPAG is a voluntary non-profit making consortium of Pharmaceutical Companies and is a principal opinion leader and influencing group for the pharmaceutical development and regulation of products for pulmonary and nasal delivery in Europe. EPAG is focussed on pharmaceutical issues relevant to inhaled drug delivery and establishes scientifically based best practice, proposes common approaches to be adopted by industry and provides consensus comment to industry and government agencies to promote safety and quality standards. This two day event will enable EPAG to make continued progress on these objectives.
Peter Scholes, CSO at Quotient Clinical, commented “We are pleased to host the latest EPAG organisational team meeting. EPAG is a highly respected industrial body committed to furthering scientific understanding of the design, development and testing of inhaled drug delivery systems. These principles are very close to our own whereby using our Translational Pharmaceutics platform we can help our customers understand and optimise formulation and device performance for inhaled and other dosage forms based on clinical data”.